可切除非小细胞肺癌术后辅助治疗进展

Progress in Postoperative Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

肺癌是中国发病率和死亡率最高的恶性肿瘤,大约30%非小细胞肺癌(NSCLC)属于可切除范围。超过一半的可切除NSCLC患者5年内复发,复发模式多为远处转移。术后辅助治疗是改善可切除NSCLC患者生存预后、减少复发风险的有效方式。随着靶向、免疫治疗的快速发展,可切除NSCLC术后辅助治疗模式也有所改变。根据患者分期、生物标志物的不同,术后辅以化疗、放疗、靶向治疗、免疫治疗等,可以最大限度改善NSCLC术后患者预后。

Lung cancer is the malignancy with the highest morbidity and mortality in China,and approximately 30%of non-small cell lung cancer(NSCLC)are resectable.More than half NSCLC patient recurs within 5 years,and the recurrence pattern is mostly distant metastasis.Postoperative adjuvant therapy is an effective way to improve the survival prognosis and reduce the risk of recurrence in patients with resectable NSCLC.With the rapid development of targeted and immunotherapy,the pattern of postoperative adjuvant therapy for resectable NSCLC has changed.According to the different stages of patients and biomarkers,postoperative adjuvant chemotherapy,radiotherapy,targeted therapy,immunotherapy and so on can maximize the improvement of the prognosis of NSCLC patients.